Recurrent Glioblastoma
Conditions
Brief summary
This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To estimate the efficacy of hypoxia inducible factor (HIF)-2 alpha inhibitor PT2385 (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology, RANO, criteria) in patients with recurrent glioblastoma. SECONDARY OBJECTIVES: I. To estimate the efficacy of PT2385 as measured by progression free and overall survival in patients with recurrent glioblastoma. II. To determine the safety of oral PT2385 in patients with recurrent glioblastoma. TERTIARY OBJECTIVES: I. To describe the pharmacokinetic and pharmacodynamic properties of PT2385 in patients with recurrent glioblastoma. II. To describe baseline intratumoral hypoxia using novel, advanced magnetic resonance (MR)-based neuroimaging sequences in patients with recurrent glioblastoma. III. To explore genetic polymorphisms involved in the metabolism of PT2385. OUTLINE: Patients receive HIF-2 alpha inhibitor PT2385 orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 2 months for 2 years and every 6 months thereafter.
Interventions
DRUGHIF-2alpha Inhibitor PT2385
Given PO
OTHERPharmacological Study
Correlative studies
OTHERLaboratory Biomarker Analysis
Correlative studies
Correlative studies
Sponsors
National Cancer Institute (NCI)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Patients must have histologically confirmed glioblastoma that is progressive or recurrent following radiation therapy and temozolomide according to the Response Assessment in Neuro-Oncology (RANO) criteria with: * New contrast-enhancing lesion outside of radiation field on decreasing, stable, or increasing doses of corticosteroids * Increase by \>= 25% in the sum of the products of perpendicular diameters between the postradiotherapy scan with the smallest tumor measurement and a scan at least 12 weeks from completion of radiation therapy (RT) + temozolomide (TMZ), on stable or increasing doses of corticosteroids \*\* Note: clinical deterioration not attributable to concurrent medication or comorbid conditions is sufficient to declare progression on current treatment but not for entry onto a clinical trial for recurrence * Tumor O(6)-methylguanine-DNA-methyltransferase (MGMT) methylation status must be available; results of routinely used methods for MGMT methylation testing (e.g. mutagenically separated polymerase chain reaction, (MSPCR), or quantitative polymerase chain reaction (PCR)) are acceptable * Patients must have a tumor tissue form indicating availability of archived tissue from a previous surgery for glioblastoma, completed and signed by a pathologist * Patients must have measurable (defined by at least 1 cm x 1 cm) contrast-enhancing disease by magnetic resonance imaging (MRI) imaging within 21 days of starting treatment * Patients must be able to undergo MRI of the brain with gadolinium; patients must be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 5 days) prior to this baseline MRI * Patients must be in first recurrence of glioblastoma following radiation therapy and temozolomide * Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible: * 12 weeks from the completion of radiation * 6 weeks from a nitrosourea chemotherapy * 3 weeks from a non-nitrosourea chemotherapy * 4 weeks from any investigational (not Food and Drug Administration (FDA)-approved) agents * 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.) * Patients must have a Karnofsky performance status \>= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others) * Absolute neutrophil count \>= 1,500/microliter (mcL) * Platelets \>= 100,000/mcL * Hemoglobin \>= 9 g/dL * Total bilirubin =\< institutional upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT))/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT)) =\< 4 x institutional upper limit of normal * Creatinine =\< institutional upper limit of normal OR creatinine clearance \>= 60 ml/min/1.73m\^2 for patients with creatinine levels above institutional normal * Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT) =\< 1.5 x institutional upper limit of normal * Patients must be able to provide written informed consent * Women of childbearing potential must have a negative serum pregnancy test prior to study start; women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug * Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for \>= five years * Patients must be able to swallow tablets
Exclusion criteria
* • Patients receiving any other investigational agents are ineligible * Patients must not have received prior anti- Vascular endothelial growth factor (VEGF) therapy including bevacizumab (i.e. patients must be bevacizumab naive) * Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PT2385 are ineligible * Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of PT2385 * Patients with a history of bleeding diathesis are ineligible * Patients who have not recovered to \< Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to prior therapy are ineligible * Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385 * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Radiographic Response as Assessed by the RANO Criteria | Up to 2 years | Tumor radiographic response assessed by Response Assessment in Neuro-Oncology (RANO) criteria. * Complete Response (CR) = no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status * Partial Response (PR) = ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status * Stable Disease (SD) = \<50% reduction to \<25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status * Progressive Disease (PD) = ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Assessed up to 2 years | PFS (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval. Definition of PFS is date treatment started to the date of progression. |
| Overall Survival | From the date of treatment start to the date of death occurrence/or censored at the time of last known alive, assessed up to 2 years | Overall survival (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval. |
| Incidence of Grade 3 and Grade 4 Adverse Events | Up to 1 year | Number of participants experiencing grade 3 and grade 4 adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics for PT2385 Drug Exposure | Day 15 cycle 1 | Drug exposure levels in 3 groups: Cmin \>1000ng/mL; Cmin: 300-1000 ng/mL and Cmin \<300ng/mL |
| Determine Association Between Baseline Tumor Acidity and PT2385 (Imaging) | At baseline | Baseline Tumor acidity was measured using pH-weighted amine chemical exchange saturation transfer (CEST) MRI contrast on the Magnetic Resonance Imaging R\^2 = reversible transverse relaxation rate (and is proportional to oxygen extraction and thus hypoxia). MTR = MTRasym the asymmetry in the magnetization transfer ratio at 3ppm from water (and it is a surrogate of tumor acidity (MTR) pH quantitative measure of the acidity or basicity (pH) of aqueous or other liquid solutions. Lower pH values correspond to solutions which are more acidic in nature, while higher values correspond to solutions which are more basic or alkaline. Exp = exposure Acid = Acidity Perit Tiss = Peritumoral Tissue Enh Tum = Enhancing Tumor DurTx = Duration treatment |
| Pharmacokinetics (Cmin) for PT2385 | Day 15 cycle 1 | Minimum concentration (Cmin) on Day 15 of cycle 1. * Cycle 1, Week 1, Day 1, Pre-dose 1: within 15 minutes prior to dose * Cycle 1, Week 1, Day 1, 6 Hours Post-dose 1: 6 hours +/- 15 minutes post-dose * Cycle 1, Week 3, Day 15, Pre-dose 1: within 30 minutes prior to dose |
Countries
United States
Participant flow
Recruitment details
Enrollment Sept 14, 2017 - March 9, 2018, all glioblastoma multiforme (GBM) patients
Participants by arm
| Arm | Count |
|---|---|
| Treatment (HIF-2 Alpha Inhibitor PT2385) Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Pharmacological Study
Laboratory Biomarker Analysis
Pharmacogenomic Study
HIF-2alpha Inhibitor PT2385: Given PO
Pharmacological Study: Correlative studies
Laboratory Biomarker Analysis: Correlative studies
Pharmacogenomic Study: Correlative studies | 24 |
| Total | 24 |
Baseline characteristics
| Characteristic | Treatment (HIF-2 Alpha Inhibitor PT2385) |
|---|---|
| Age, Continuous | 62.1 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Extent of tumor resection Biopsy | 2 Participants |
| Extent of tumor resection Gross total resection | 14 Participants |
| Extent of tumor resection Subtotal resection | 8 Participants |
| Karnofsky Performance Status Score | 80 score on a scale |
| MGMT Promoter Status Indeterminate | 1 Participants |
| MGMT Promoter Status Methylated | 11 Participants |
| MGMT Promoter Status Not Methylated | 12 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 22 Participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 24 |
| other Total, other adverse events | 24 / 24 |
| serious Total, serious adverse events | 6 / 24 |
Outcome results
Primary
Tumor Radiographic Response as Assessed by the RANO Criteria
Tumor radiographic response assessed by Response Assessment in Neuro-Oncology (RANO) criteria. * Complete Response (CR) = no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status * Partial Response (PR) = ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status * Stable Disease (SD) = \<50% reduction to \<25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status * Progressive Disease (PD) = ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.
Time frame: Up to 2 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Tumor Radiographic Response as Assessed by the RANO Criteria | complete response | 0 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Tumor Radiographic Response as Assessed by the RANO Criteria | partial response | 0 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Tumor Radiographic Response as Assessed by the RANO Criteria | stable | 7 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Tumor Radiographic Response as Assessed by the RANO Criteria | progression | 17 Participants |
Secondary
Incidence of Grade 3 and Grade 4 Adverse Events
Number of participants experiencing grade 3 and grade 4 adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Time frame: Up to 1 year
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Incidence of Grade 3 and Grade 4 Adverse Events | grade 3 anemia | 1 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Incidence of Grade 3 and Grade 4 Adverse Events | grade 3 Hyperglycemia | 1 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Incidence of Grade 3 and Grade 4 Adverse Events | grade 3 hyponatremia | 2 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Incidence of Grade 3 and Grade 4 Adverse Events | grade 3 Hypoxia | 2 Participants |
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Incidence of Grade 3 and Grade 4 Adverse Events | grade 4 Hypoxia | 1 Participants |
Secondary
Overall Survival
Overall survival (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval.
Time frame: From the date of treatment start to the date of death occurrence/or censored at the time of last known alive, assessed up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Overall Survival | 7.7 months |
Secondary
Progression-free Survival (PFS)
PFS (in months) will be estimated using Kaplan-Meier method along with 95% confidence interval. Definition of PFS is date treatment started to the date of progression.
Time frame: Assessed up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (HIF-2 Alpha Inhibitor PT2385) | Progression-free Survival (PFS) | 1.8 months |
Other Pre-specified
Determine Association Between Baseline Tumor Acidity and PT2385 (Imaging)
Baseline Tumor acidity was measured using pH-weighted amine chemical exchange saturation transfer (CEST) MRI contrast on the Magnetic Resonance Imaging R\^2 = reversible transverse relaxation rate (and is proportional to oxygen extraction and thus hypoxia). MTR = MTRasym the asymmetry in the magnetization transfer ratio at 3ppm from water (and it is a surrogate of tumor acidity (MTR) pH quantitative measure of the acidity or basicity (pH) of aqueous or other liquid solutions. Lower pH values correspond to solutions which are more acidic in nature, while higher values correspond to solutions which are more basic or alkaline. Exp = exposure Acid = Acidity Perit Tiss = Peritumoral Tissue Enh Tum = Enhancing Tumor DurTx = Duration treatment
Time frame: At baseline
Other Pre-specified
Pharmacokinetics (Cmin) for PT2385
Minimum concentration (Cmin) on Day 15 of cycle 1. * Cycle 1, Week 1, Day 1, Pre-dose 1: within 15 minutes prior to dose * Cycle 1, Week 1, Day 1, 6 Hours Post-dose 1: 6 hours +/- 15 minutes post-dose * Cycle 1, Week 3, Day 15, Pre-dose 1: within 30 minutes prior to dose
Time frame: Day 15 cycle 1
Other Pre-specified
Pharmacokinetics for PT2385 Drug Exposure
Drug exposure levels in 3 groups: Cmin \>1000ng/mL; Cmin: 300-1000 ng/mL and Cmin \<300ng/mL
Time frame: Day 15 cycle 1